Evelo Biosciences, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Evelo Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2023.
  • Evelo Biosciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$11.2M, a 61.5% increase year-over-year.
  • Evelo Biosciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$76.7M, a 33.2% increase year-over-year.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$108M, a 6.01% increase from 2021.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$115M, a 25.6% decline from 2020.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2020 was -$91.9M, a 6.4% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$76.7M -$11.2M +$17.9M +61.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$94.6M -$19.6M +$10M +33.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$105M -$24.9M +$3.84M +13.4% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$108M -$21.1M +$6.47M +23.5% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-16
Q3 2022 -$115M -$29.1M +$3.66M +11.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$119M -$29.6M -$1.93M -6.98% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$117M -$28.7M -$1.27M -4.61% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$115M -$27.6M +$639K +2.27% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$116M -$32.7M -$12.5M -62.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$104M -$27.7M -$7.41M -36.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$96.1M -$27.5M -$4.21M -18.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$91.9M -$28.2M -$5.53M -24.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$86.4M -$20.2M +$1.31M +6.11% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-10-29
Q2 2020 -$87.7M -$20.2M +$1.14M +5.34% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$88.8M -$23.3M -$2.46M -11.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 -$86.4M -$22.7M -$6.68M -41.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$79.7M -$21.5M -$5.04M -30.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 -$74.6M -$21.4M -$6.16M -40.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 -$68.5M -$20.8M -$10.4M -99.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$58.1M -$16M -$7.93M -98.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 -$50.2M -$16.5M -$8.42M -105% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$41.8M -$15.2M -$9.01M -145% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$32.7M -$10.4M -$5.22M -100% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-03
Q4 2017 -$27.5M -$8.07M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-14
Q3 2017 -$8.04M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 -$6.22M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$5.21M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.